Steward Partners Investment Advisory LLC Sells 18,400 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Steward Partners Investment Advisory LLC reduced its stake in Edwards Lifesciences by 18.3%, selling 18,400 shares and ending the quarter with 81,897 shares worth approximately $5.9 million.
• In the first quarter, other institutional investors also adjusted their positions, with American Century Companies Inc. increasing its holdings by 9.3% and **Ethic Inc.** by **39.1%**, highlighting significant investor interest.
• Edwards Lifesciences reported a quarterly earnings per share of $0.67, surpassing analyst estimates, and experienced an 11.9% year-over-year revenue growth, indicating strong financial performance.

Steward Partners Investment Advisory LLC trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 18.3% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 81,897 shares of the medical research company's stock after selling 18,400 shares during the quarter. Steward Partners Investment Advisory LLC's holdings in Edwards Lifesciences were worth $5,936,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Vega Investment Solutions bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $27,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $27,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $29,000. Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $29,000. Finally, Global X Japan Co. Ltd. grew its position in Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president directly owned 50,356 shares in the company, valued at approximately $3,897,554.40. The trade was a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,584 shares of company stock valued at $1,897,762. 0.34% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Truist Financial upped their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a report on Friday, July 25th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. Canaccord Genuity Group upped their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Finally, William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Trading Up 0.7%

Edwards Lifesciences stock traded up $0.5950 during mid-day trading on Friday, reaching $81.7550. 3,076,141 shares of the company traded hands, compared to its average volume of 4,195,043. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm's 50 day moving average price is $77.58 and its 200 day moving average price is $74.72. The firm has a market capitalization of $48.00 billion, a price-to-earnings ratio of 11.76, a P/E/G ratio of 3.95 and a beta of 1.08. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.